GLP-1s and Kidney Outcomes: The FLOW Trial, Explained

The GLP-1 story started with blood sugar, expanded to weight, and then to cardiovascular events. The FLOW trial pushed it into the kidney. It asked a focused question: in people with type 2 diabetes and chronic kidney disease, does semaglutide slow the decline toward kidney failure? The answer was one of the more clinically meaningful findings in the class — but it is worth being precise about exactly which patients it applies to.

What FLOW measured

FLOW, published in the New England Journal of Medicine in 2024, was the first dedicated kidney-outcomes trial of a GLP-1 receptor agonist. It randomized 3,533 participants who already had both type 2 diabetes and chronic kidney disease to once-weekly subcutaneous semaglutide 1.0 mg or placebo, on top of standard care, with a median follow-up of 3.4 years.

The primary outcome was a composite of major kidney events: kidney failure, a substantial loss of kidney function, and death from kidney or cardiovascular causes.

FLOW’s headline result was a 24% reduction in the risk of the primary composite outcome — a hazard ratio of 0.76 — in this specific high-risk group. It does not show that GLP-1s protect the kidneys of people who don’t already have kidney disease.

That boundary is the most commonly mangled part of the story. A positive trial in advanced-risk patients is not a license to generalize to anyone curious about kidney health.

How to read the result

A few framing points help keep the finding in proportion:

Outcome	Effect with semaglutide
Primary composite kidney outcome	24% reduction (HR 0.76)
Major cardiovascular events	18% reduction (HR 0.82)
Death from any cause	20% reduction (HR 0.80)

• The population was high-risk by design. Benefits in such groups often look larger in relative terms precisely because the baseline event rate is high.
• It’s a composite outcome. Composite endpoints bundle several events; it’s worth knowing which components contributed rather than assuming each is equally affected.
• Mechanism is still being worked out. Some benefit may be indirect — through better glucose, blood pressure, and weight — and some may be more direct kidney effects. The trial does not settle the split.

What it does not establish

• That GLP-1s prevent kidney disease in people who don’t have it.
• That the effect is identical across every agent in the class.
• That the benefit is fully independent of the cardiovascular and metabolic improvements that come along with it.

The takeaway

For people with type 2 diabetes and chronic kidney disease, FLOW is genuinely important: it added the kidney to the list of organs where a GLP-1 changed hard outcomes, not just lab numbers. For everyone else, it is encouraging context, not a personal indication. The cleanest way to read a single trial is to anchor on who was actually in it — and FLOW’s strength is also its limit. This is a decision to make with a clinician who knows your kidney function, not a reason to assume protection you haven’t been shown to need.

Sources

• FLOW trial demonstrates kidney, cardiovascular benefits of semaglutide (ADA Meeting News)
• Cardiovascular outcomes with semaglutide by severity of CKD: the FLOW trial (PMC)